Canada's HIV Drugs Market size stood at USD 789.8 million in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

The Public Health Agency of Canadas (PHAC) 2018 HIV Surveillance Reportrevealed that the number of new HIV rates in Canada is on the rise for the fourth consecutive year. They have increased by 25.3% since 2014. Currently, more than 68,000 Canadians are living with HIV, with 14% unaware that they have been infected. The diagnosis rate for males in 2019 was higher than that for females (7.9 versus 3.4 per 100,000 population, respectively).The Canadian AIDS Society (CAS) claimed that the rise in HIV rates is primarily due to funding cuts to local HIV organizations receiving assistance from PHACs HIV and Hepatitis C Community Action Fund in 2016. Nearly 40% of community-based HIV organizations lost their funding for not aligning with the Canadian governments new focus on prevention.



Market Drivers

The major factors that boost the HIV drug market growth include an increase in the prevalence of HIV, increasing number of blood transfusions and blood donations, benefits offered by Point-of-care instruments & kits, increasing government initiatives, rise in treatment & diagnosis rate. A vital factor driving the HIV market growth is the government and various NGOs to provide at-risk individuals with greater accessibility to disease testing and treatment for infected persons. As part of a global movement to eliminate sexually transmitted and blood-borne infections (STBBI) as a health concern by 2028, the Public Health Agency of Canada (PHAC) published reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2028. A pan Canadian STBBI framework for action. This framework and its associated government of Canada action plan demonstrate a commitment to reducing the burden of STBBI in Canada through the core pillars of prevention, testing, initiation of care and treatment, and ongoing maintenance and support.